Practitioner 2010;255 (1743): 8

Weighing up the risks and benefits of high-dose statin therapy

20 Sep 2011Pais-up subscribers

A recent meta-analysis, published in JAMA, has suggested an increase in the risk of developing diabetes with high-dose statin therapy compared with moderate-dose therapy. However, the cardiovascular benefits appear to outweigh the risk of diabetes.The researchers analysed large, randomised controlled, hard end point studies that compared intensive with moderate-dose statin therapy and included more than 1,000 patients followed up for longer than a year. The trials studied in the meta-analysis were PROVE IT-TIMI 22, A to Z, TNT, IDEAL, and SEARCH. These five trials included 32,752 patients without diabetes mellitus at baseline.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article